Overview
NICE is unable to make a recommendation on sacituzumab govitecan (Trodelvy) for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments in adults. This is because the company did not provide an evidence submission.
Last reviewed: 13 August 2025
Next review: We will review this decision if the company decides to make a submission.